Sort   by:  
 Page size 
UnknownCRISPR/Cas9 gene targeting plus nanopore DNA sequencing with the plasmid pBR322 in the classroom.
Not available
S-EPMC11360410 | biostudies-literature
Models,MultiomicsHCC1954 Breast Cell Line Long-term ErbB Network
Background Despite promising progress in targeted breast cancer therapy, drug resistance remains challenging. The monoclonal antibody drugs trastuzumab and pertuzumab as well as the small molecule inhibitor erlotinib were designed to prevent ErbB-2 and ErbB-1 receptor induced deregulated protein sig...
2698 | Cell Collective
Models,MultiomicsBT474 Breast Cell Line Short-term ErbB Network
Background Despite promising progress in targeted breast cancer therapy, drug resistance remains challenging. The monoclonal antibody drugs trastuzumab and pertuzumab as well as the small molecule inhibitor erlotinib were designed to prevent ErbB-2 and ErbB-1 receptor induced deregulated protein sig...
2699 | Cell Collective
Models,MultiomicsSKBR3 Breast Cell Line Long-term ErbB Network
Background Despite promising progress in targeted breast cancer therapy, drug resistance remains challenging. The monoclonal antibody drugs trastuzumab and pertuzumab as well as the small molecule inhibitor erlotinib were designed to prevent ErbB-2 and ErbB-1 receptor induced deregulated protein sig...
2703 | Cell Collective
Models,MultiomicsBT474 Breast Cell Line Long-term ErbB Network
Background Despite promising progress in targeted breast cancer therapy, drug resistance remains challenging. The monoclonal antibody drugs trastuzumab and pertuzumab as well as the small molecule inhibitor erlotinib were designed to prevent ErbB-2 and ErbB-1 receptor induced deregulated protein sig...
2697 | Cell Collective
Models,MultiomicsHCC1954 Breast Cell Line Short-term ErbB Network
Background Despite promising progress in targeted breast cancer therapy, drug resistance remains challenging. The monoclonal antibody drugs trastuzumab and pertuzumab as well as the small molecule inhibitor erlotinib were designed to prevent ErbB-2 and ErbB-1 receptor induced deregulated protein sig...
2700 | Cell Collective
Models,MultiomicsSKBR3 Breast Cell Line Short-term ErbB Network
Background Despite promising progress in targeted breast cancer therapy, drug resistance remains challenging. The monoclonal antibody drugs trastuzumab and pertuzumab as well as the small molecule inhibitor erlotinib were designed to prevent ErbB-2 and ErbB-1 receptor induced deregulated protein sig...
2701 | Cell Collective
Sort   by:  
 Page size